Anzeige
Mehr »
Freitag, 11.07.2025 - Börsentäglich über 12.000 News
Der nächste Volltreffer direkt neben einer brandneuen Entdeckung! Kupfer im Höhenflug!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
251 Leser
Artikel bewerten:
(1)

Think Research Announces Sale of BioPharma Services

Sale of BioPharma subsidiary is a key component of Think's strategic plan to refocus on core software assets.

Divestiture will drive enhanced product innovation and support improved customer service.

TORONTO, ON / ACCESSWIRE / June 13, 2024 / Think Research Corporation ("Think Research" or the "Company"), a company focused on transforming healthcare through digital health software solutions, is pleased to announce that its subsidiary, BioPharma Services ("BioPharma"), has been sold to HEALWELL AI. The sale is a key component of Think's strategic plan to sharpen its focus on its core software and content business and enhance its customer service offerings.

Committed to revolutionizing healthcare with innovative technology and evidence-based solutions, the divestiture of BioPharma enables Think to dedicate more resources to improving healthcare access and supporting healthcare professionals in making informed clinical decisions with our state-of-the-art digital health tools.

Sachin Aggarwal, CEO of Think Research said, "We are excited about this strategic move. The sale of BioPharma enables us to operate more adeptly and effectively, empowering us to focus on enhancing our core suite of products and innovations to better respond to our customers' evolving needs."

BioPharma is a leading contract research organization (CRO) specializing in Phase 1 clinical trials, and was initially acquired by Think in 2021. Focusing on scientific integrity, operational excellence, and adaptive processes tailored to each client's needs, BioPharma Services has established a reputation for delivering high-quality results in the pharmaceutical and biotech industries.

The sale marks a significant step in Think's mission to transform healthcare and support informed clinical decisions. Think remains fully committed to upholding its existing contracts, privacy obligations, and data security standards. Clients can expect a seamless continuation of services without any disruption.

About Think Research Corporation

Think Research Corporation is an industry leader in delivering knowledge-based digital health software solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process and standardization of care to facilitate better healthcare outcomes. The Company gathers, develops, and delivers knowledge-based solutions globally to customers including enterprise clients, hospitals, health regions, healthcare professionals, and/or governments. The Company has gathered a significant amount of data by building its repository of knowledge through its network and group of companies.

Think licenses its solutions to over 14,200 facilities for over 320,000 primary care, acute care, and long-term care doctors, nurses and pharmacists that rely on the content and data provided by Think to support their practices. Millions of patients and residents annually receive better care due to the essential data that Think produces, manages and delivers.

For further information: Mark Sakamoto, Executive Vice President, Think Research Corporation, Direct: 416.388.7119, mark.sakamoto@thinkresearch.com

SOURCE: Think Research



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.